• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Clinical predictors of acute response with quetiapine in psychotic mood disorders.
【24h】

Clinical predictors of acute response with quetiapine in psychotic mood disorders.

机译：喹硫平在精神病性情绪障碍中急性反应的临床预测指标。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: In controlled studies of patients with schizophrenia, the atypical antipsychotic quetiapine, 300 mg/day, has been shown to be as effective in the treatment of positive and negative symptoms as haloperidol. However, little is known about the efficacy of quetiapine in patients with psychotic mood disorders. The purpose of this study was to assess the efficacy of quetiapine in the treatment of psychotic mood disorders in comparison with nonaffective psychotic disorders and identify clinical factors associated with quetiapine response. METHOD: In a naturalistic setting, by reviewing medical records, we assessed response to quetiapine and factors associated with response to quetiapine in 145 consecutive patients newly treated with the drug at a nonprofit academic psychiatric hospital. These patients had received a discharge diagnosis of bipolar disorder (manic, mixed, or depressive type), major depression with psychotic features, schizophrenia, schizoaffective disorder (bipolar or depressive type), delusional disorder, or psychosis not otherwise specified (NOS) according to DSM-IV criteria. RESULTS: Patients with a diagnosis of bipolar disorder, manic, mixed, or depressed and schizoaffective disorder, bipolar type displayed higher response rates (> 74%) compared with patients with schizophrenia. However, this finding did not achieve statistical significance. A diagnosis of major depression with psychotic features (p = .02) and longer duration of illness (p = .03) were associated with less chance of responding. CONCLUSION: Quetiapine may be a useful alternative or adjunctive treatment for patients with bipolar and schizoaffective disorders.
机译：背景：在对精神分裂症患者的对照研究中，非典型的抗精神病药物喹硫平（300毫克/天）已被证明与氟哌啶醇一样有效。但是，人们对于喹硫平在精神病性情绪障碍患者中的​​功效知之甚少。这项研究的目的是评估喹硫平与非情感性精神病相比，在治疗精神病性情绪障碍中的功效，并确定与喹硫平反应相关的临床因素。方法：在自然主义的环境中，通过回顾医学记录，我们评估了在一家非营利性学术精神病医院新近接受治疗的145例连续患者对喹硫平的反应以及与喹硫平反应相关的因素。这些患者接受了双相情感障碍（躁狂，混合或抑郁型），具有精神病特征的重度抑郁症，精神分裂症，精神分裂性情感障碍（双相情感障碍或抑郁型），妄想障碍或未另作说明的精神病（NOS）的出院诊断。 DSM-IV标准。结果：与精神分裂症患者相比，诊断为躁郁症，躁狂，混合性或抑郁和精神分裂症的患者，躁郁症表现出更高的缓解率（> 74％）。但是，这一发现没有达到统计学意义。诊断为具有精神病特征的重度抑郁（p = .02）和病程较长（p = .03）的情况下，反应的机会较小。结论喹硫平可能是双相情感障碍和精神分裂症患者的一种有用的替代或辅助治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号